Abstract
A paracorporeal left ventricular assist device (LVAD) with a capacity to pump 8 L/min of blood was employed in a clinical trial, and this report details the first survivor. A 60-year-old man could not be separated from the pump oxygenator following coronary artery bypass grafting, and, therefore, an LVAD was employed. Almost the entire left ventricular workload was assumed by the mechanical pump so that the myocardium was allowed to rest and recover. The LVAD support was continued for 105 hours. It provided satisfactory total body perfusion with maintenance of good hemodynamics--without serious deleterious effects on hematologic factors. The patient is alive and active without cardiac symptoms 16 months after his operation. The total experience with 13 LVAD implantations warrants continuation of the clinical trials in selected patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
